Andrew Gengos - Jun 17, 2021 Form 3 Insider Report for Cyteir Therapeutics, Inc. (CYT)

Role: Chief Business Officer
Signature: By: /s/ Andrew Gengos
Stock symbol: CYT
Transactions as of: Jun 17, 2021
Transactions value $: $0
Form type: 3
Date filed: 6/17/2021, 09:15 PM
Next filing: Feb 24, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	CYT	Common Stock						73.5K	Jun 17, 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	CYT	Stock Option (Right to Buy)							Jun 17, 2021	Common Stock	55.2K	$1.19	Direct	F2
holding	CYT	Stock Option (Right to Buy)							Jun 17, 2021	Common Stock	147K	$1.19	Direct	F3
holding	CYT	Stock Option (Right to Buy)							Jun 17, 2021	Common Stock	103K	$7.09	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 4,595 shares acquired upon early exercise of an option, which are subject to forfeiture until they vest.
F2	The option vests as to 75% of the underlying shares of common stock on February 24, 2023, and as to the remaining shares underlying the award in 12 equal monthly installments thereafter, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.
F3	The option vests as to 25% of the underlying shares of common stock on February 24, 2021, and as to the remaining shares underlying the award in 36 equal monthly installments thereafter, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.
F4	The option will become exercisable as to 1/36th of the underlying shares of common stock at the end of each successive one-month period following the vesting commencement date, February 5, 2021, until the option is fully vested on the third anniversary of the vesting commencement date, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.